Instructions for Hylak Forte Drops 100 ml
English product name
Hylak Forte
Release form
d/ingest drops: 1.1 ml or 2.2 ml sachet 30 pcs; fl 30 ml or 100 ml with drip plug
d/ingestion drops (cherry flavoured): fl 30 ml or 100 ml with drip plug
Description:
Drops for ingestion (with the taste of cherry) in the form of a transparent or slightly murky solution of yellowish-brown color with the characteristic smell of cherry.
100 ml
aquatic substrate of metabolism products Escherichia coli DSM 4087* 24.9481 g
aquatic substrate of metabolism products Enterococcus faecalis DSM 4086* 12.4741 g
aquatic substrate of metabolism products Lactobacillus acidophilus DSM 4149* 12.4741 g
aquatic substrate for metabolism products Lactobacillus helveticus DSM 4183* 49.896 g
* substrates contain lactose.
Auxiliary substances:
- sodium phosphate heptahydrate - 1.159 g,
- dipotassium phosphate - 1.265 g,
- lactic acid - 2.5-6.25 g,
- phosphoric acid concentrated - 0.352 g,
- potassium sorbate - 0.1114 g,
- citric acid monohydrate - 0.0322 g,
- sodium saccharinate - 0.02 g,
- sodium cyclamate - 0.2 g,
- aromatizator cream - 0.2 g,
- aromatizator cherry - 0.5 g,
- water - up to 100 ml.
30 ml - bottles of dark glass (1) with drip-plug and plastic lid with first opening control - cardboard packs.
100 ml - bottles of dark glass (1) with drip-plug and plastic lid with first opening control - cardboard packs.
ATC codes
A07FA Biological antidiarrhoeal preparations regulating the balance of intestinal microflora
Clinical-pharmacological groups / Group affiliation
Preparation for regulating the balance of intestinal microflora
Active substance
aquatic substrate of metabolism products Escherichia coli DSM 4087
aquatic substrate of metabolism products Lactobacillus acidophilus DSM 4149
aquatic substrate of metabolism products Lactobacillus helveticus DSM 4183
aquatic substrate of metabolism products Enterococcus faecalis DSM 4086
Pharmacotherapy group
Anti-diarrhoea
Testimony:
- disruption of the physiological flora of the small and large intestines (during and after antibiotic or sulfanilamide treatment, radiation therapy);
- Digestive deficiency syndrome, dyspepsia
- diarrhea, flatulence, constipation;
- gastroenteritis, colitis;
- Bowel syndrome (chronic, atrophic gastroenteritis);
- GI disorders caused by climate change;
- hypo- and anacidal states;
- enterogenic diseases of the gall bladder and liver;
- allergic skin diseases (urticaria, endogenous chronic eczema);
- salmonellosis in the stage of reconvalescence (including in infants).
Method of use, course and dosage:
Hylak Forte is taken inside before or during meals, diluting in a small amount of liquid, excluding milk.
The preparation is prescribed 3 times/day.
Adults are prescribed the drug 40-60 drops (2.2-3.3 ml) for administration; children - 20-40 drops (1.1-2.2 ml) per reception; Babies receive 15-30 drops.
In infants, it is recommended to use the drug in vials.
Once the condition improves, the daily dose can be reduced by half.
Use in children
Children are prescribed the drug 20-40 drops 3 times / day; Infants - 15-30 drops 3 times per day. Once the condition improves, the initial daily dose of Hylak Forte can be reduced by half.
- Nosology (ICD codes)
- A02
- Other salmonella infections
- A09
- Other gastroenteritis and colitis of infectious and unspecified origin
- K29
- Gastritis and duodenitis
- K30
- Functional dyspepsia (digestive disorder)
- K52
- Other non-infectious gastroenteritis and colitis
- K59.0
- Constipation
- K59.1
- Functional diarrhea
- K63.8
- Other refined bowel diseases
- L20.8
- Other atopic dermatitis (neurodermatitis, eczema)
- L50
- Urticaria
- R14
- Flatulence and related states (including bloating, burping)
Pharmacological effect:
The natural physiological microflora of the intestine can be significantly impaired by external influences such as antibiotic therapy, radiation, gastric surgery, as well as by inappropriate and unusual nutrition, water change, climate change and other conditions.
Hylak Forte regulates the balance of intestinal microflora and normalizes its composition. Due to the presence of normal microflora exchange products in the composition of the preparation, Hylak Forte promotes the restoration of normal intestinal microflora biologically and allows the preservation of the physiological and biological functions of the intestinal mucous membrane.
The biosynthetic lactic acid contained in the preparation and the buffer salts thereof restore the normal acidity value in the gastrointestinal tract, irrespective of the patient's increased or decreased acidity.
The natural synthesis of vitamins B and K is normalised in the background of accelerating development of normal intestinal symbionts under the action of Hylak Forte. The short-chain volatile fatty acids contained in Hylak Forte provide restoration of damaged intestinal microflora in case of infectious diseases of gastrointestinal tract, stimulate regeneration of intestinal epithelial cells, restore disturbed water-electrolyte balance in intestinal tract.
Hylak Forte has been shown to enhance the body's defences by stimulating the immune response.
The use of Hylak Forte results in the accelerated elimination of salmonella in infants after salmonella enteritis, which is caused by the growth of acidophilic anaerobic flora and its subsequent antagonistic effect on salmonella.
